WallStSmart

GlucoTrack Inc (GCTK)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

MRK leads profitability with a 4.8% profit margin vs 0.0%. GCTK trades at a lower P/E of 0.1x. MRK earns a higher WallStSmart Score of 36/100 (F).

GCTK

Avoid

27

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 6.7Quality: 4.5
Piotroski: 2/9Altman Z: -34.50

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GCTK.

MRKSignificantly Overvalued (-78.2%)

Margin of Safety

-78.2%

Fair Value

$83.04

Current Price

$148.78

$65.74 premium

UndervaluedFair: $83.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GCTK2 strengths · Avg: 10.0/10
P/E RatioValuation
0.1x10/10

Attractively priced relative to earnings

Debt/EquityHealth
-0.0110/10

Conservative balance sheet, low leverage

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$365.34B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

GCTK4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.04M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.8x4/10

Trading at 8.8x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : GCTK

The strongest argument for GCTK centers on P/E Ratio, Debt/Equity.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : GCTK

The primary concerns for GCTK are Revenue Growth, EPS Growth, Market Cap.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

GCTK carries more volatility with a beta of 0.66 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (36/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GlucoTrack Inc

HEALTHCARE · MEDICAL DEVICES · USA

GlucoTrack, Inc., a medical device company, designs, develops and markets noninvasive glucose monitoring devices for people with diabetes and prediabetes in Europe and Asia Pacific. The company is headquartered in Or Yehuda, Israel.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?